GlassScriptPhysician profile
Tiffany Leann Gregory
NPI 1962936146
$2,631.22
in general payments reported to CMS, 2019-2025
18 companies · $20.62 in 2025
The $20.62 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $676 · 2023: $899 · 2024: $153 · 2025: $20.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $488.59 | 2021-2023 | |
| Abbott Laboratories | $405.43 | 2021-2023 | Cardiomems, Mitraclip, Absolute Pro |
| Merck Sharp & Dohme LLC | $272.99 | 2021-2024 | Verquvo |
| Impulse Dynamics (USA) INC. | $242.32 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $214.22 | 2021-2023 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.41 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.88 | 2021-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $115.50 | 2021-2023 | Xarelto |
| Pfizer INC. | $109.48 | 2021-2022 | |
| Daiichi Sankyo INC. | $81.96 | 2023-2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $78.40 | 2022-2023 | Onpattro |
| Scpharmaceuticals INC. | $73.81 | 2023-2024 | |
| Vifor Pharma, INC. | $51.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.46 | 2023 | Camzyos |
| Cvrx, INC. | $42.88 | 2024 | Barostim Neo System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $35.98 | 2024 | Impella |
| Atricure, INC. | $21.86 | 2023 | |
| Lemaitre Vascular, INC. | $20.62 | 2025 | Restoreflow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.